It is premature to envisage the potential of PEGPH20 in pancreatic cancer
Due to the small number of patients treated to date: While the results look intriguing, particularly
in the patients who express high levels of HA, the number of patients is too low to draw a conclusion about clinical utility. In addition, the pancreatic cancer space is becoming increasingly competitive with the recent approval of Abraxane as well as a number of newly-initiated or ongoing Phase III studies of competing therapies. Although cross-trial comparison is fraught with many confounding factors, median survival of 8.5 months in patients treated with Abraxane/gemcitabine combination in the Phase III MPACT trial is longer than the median survival of 200 days in the Phase Ib trial of PEGPH20/gemcitabine combination.